Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 107 entries
Sorted by: Best Match Show Resources per page
Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery.

Current interventional cardiology reports

Laham RJ, Post M, Sellke FW, Simons M.
PMID: 11096670
Curr Interv Cardiol Rep. 2000 Aug;2(3):213-217.

Therapeutic angiogenesis is a potential new treatment strategy that promises to grow new blood vessels to the ischemic myocardium in patients with ischemic heart disease. Despite its investigation in more than 550 patients with ischemic heart disease, the concept...

Cite
Laham RJ, Post M, Sellke FW, et al. Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. Curr Interv Cardiol Rep. 2000;2(3):213-217
Laham, R. J., Post, M., Sellke, F. W., & Simons, M. (2000). Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. Current interventional cardiology reports, 2(3), 213-217.
Laham, et al. "Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery." Current interventional cardiology reports vol. 2,3 (2000): 213-217.
Laham RJ, Post M, Sellke FW, Simons M. Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. Curr Interv Cardiol Rep. 2000 Aug;2(3):213-217. PMID: 11096670.
Copy Download .nbib Format: NLM
Effect of isoflurane on the beta-adrenergic and endothelium-dependent relaxation of pig cerebral microvessels after cardiopulmonary bypass.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Park KW, Dai HB, Lowenstein E, Stambler A, Sellke FW.
PMID: 17895077
J Stroke Cerebrovasc Dis. 1998 May-Jun;7(3):168-78. doi: 10.1016/s1052-3057(98)80003-7.

We examined the direct vasomotor effect of isoflurane as well as its effect on endothelium-dependent and beta-adrenergic vasodilation of cerebral microcirculation following either normothermic cardiopulmonary bypass (CPB) or profoundly hypothermic CPB with circulatory arrest. Pigs were placed on CPB;...

Cite
Park KW, Dai HB, Lowenstein E, et al. Effect of isoflurane on the beta-adrenergic and endothelium-dependent relaxation of pig cerebral microvessels after cardiopulmonary bypass. J Stroke Cerebrovasc Dis. 1998;7(3):168-78doi: 10.1016/s1052-3057(98)80003-7.
Park, K. W., Dai, H. B., Lowenstein, E., Stambler, A., & Sellke, F. W. (1998). Effect of isoflurane on the beta-adrenergic and endothelium-dependent relaxation of pig cerebral microvessels after cardiopulmonary bypass. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 7(3), 168-78. https://doi.org/10.1016/s1052-3057(98)80003-7
Park, K W, et al. "Effect of isoflurane on the beta-adrenergic and endothelium-dependent relaxation of pig cerebral microvessels after cardiopulmonary bypass." Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association vol. 7,3 (1998): 168-78. doi: https://doi.org/10.1016/s1052-3057(98)80003-7
Park KW, Dai HB, Lowenstein E, Stambler A, Sellke FW. Effect of isoflurane on the beta-adrenergic and endothelium-dependent relaxation of pig cerebral microvessels after cardiopulmonary bypass. J Stroke Cerebrovasc Dis. 1998 May-Jun;7(3):168-78. doi: 10.1016/s1052-3057(98)80003-7. PMID: 17895077.
Copy Download .nbib Format: NLM
Therapeutic angiogenesis: potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Simons M, Laham RJ, Post M, Sellke FW.
PMID: 18034552
BioDrugs. 2000 Jul;14(1):13-20. doi: 10.2165/00063030-200014010-00002.

Therapeutic angiogenesis is a rapidly evolving approach to the treatment of advanced coronary disease. The availability of growth factors such as basic fibroblast growth factor (bFGF or FGF2) has made possible the practical clinical application of this research. In...

Cite
Simons M, Laham RJ, Post M, et al. Therapeutic angiogenesis: potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease. BioDrugs. 2000;14(1):13-20doi: 10.2165/00063030-200014010-00002.
Simons, M., Laham, R. J., Post, M., & Sellke, F. W. (2000). Therapeutic angiogenesis: potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(1), 13-20. https://doi.org/10.2165/00063030-200014010-00002
Simons, M, et al. "Therapeutic angiogenesis: potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,1 (2000): 13-20. doi: https://doi.org/10.2165/00063030-200014010-00002
Simons M, Laham RJ, Post M, Sellke FW. Therapeutic angiogenesis: potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease. BioDrugs. 2000 Jul;14(1):13-20. doi: 10.2165/00063030-200014010-00002. PMID: 18034552.
Copy Download .nbib Format: NLM
Evidence for a bicritical point in the XXZ Heisenberg antiferromagnet on a simple cubic lattice.

Physical review. E, Statistical, nonlinear, and soft matter physics

Selke W.
PMID: 21599220
Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Apr;83(4):042102. doi: 10.1103/PhysRevE.83.042102. Epub 2011 Apr 15.

The classical Heisenberg antiferromagnet with uniaxial exchange anisotropy (XXZ model) in a field on a simple cubic lattice is studied with the help of extensive Monte Carlo simulations. We analyze, in particular, various staggered susceptibilities and Binder cumulants and...

Cite
Selke W. Evidence for a bicritical point in the XXZ Heisenberg antiferromagnet on a simple cubic lattice. Phys Rev E Stat Nonlin Soft Matter Phys. 2011;83(4):042102doi: 10.1103/PhysRevE.83.042102.
Selke, W. (2011). Evidence for a bicritical point in the XXZ Heisenberg antiferromagnet on a simple cubic lattice. Physical review. E, Statistical, nonlinear, and soft matter physics, 83(4), 042102. https://doi.org/10.1103/PhysRevE.83.042102
Selke, Walter. "Evidence for a bicritical point in the XXZ Heisenberg antiferromagnet on a simple cubic lattice." Physical review. E, Statistical, nonlinear, and soft matter physics vol. 83,4 (2011): 042102. doi: https://doi.org/10.1103/PhysRevE.83.042102
Selke W. Evidence for a bicritical point in the XXZ Heisenberg antiferromagnet on a simple cubic lattice. Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Apr;83(4):042102. doi: 10.1103/PhysRevE.83.042102. Epub 2011 Apr 15. PMID: 21599220.
Copy Download .nbib Format: NLM
Commensurate-incommensurate phase transitions and wetting in a lattice-gas model with axially competing interactions.

Physical review. B, Condensed matter

Rujan P, Selke W, Uimin G.
PMID: 9936891
Phys Rev B Condens Matter. 1985 Dec 01;32(11):7453-7468. doi: 10.1103/physrevb.32.7453.

No abstract available.

Cite
Rujan P, Selke W, Uimin G. Commensurate-incommensurate phase transitions and wetting in a lattice-gas model with axially competing interactions. Phys Rev B Condens Matter. 1985;32(11):7453-7468doi: 10.1103/physrevb.32.7453.
Rujan, P., Selke, W., & Uimin, G. (1985). Commensurate-incommensurate phase transitions and wetting in a lattice-gas model with axially competing interactions. Physical review. B, Condensed matter, 32(11), 7453-7468. https://doi.org/10.1103/physrevb.32.7453
Rujan, et al. "Commensurate-incommensurate phase transitions and wetting in a lattice-gas model with axially competing interactions." Physical review. B, Condensed matter vol. 32,11 (1985): 7453-7468. doi: https://doi.org/10.1103/physrevb.32.7453
Rujan P, Selke W, Uimin G. Commensurate-incommensurate phase transitions and wetting in a lattice-gas model with axially competing interactions. Phys Rev B Condens Matter. 1985 Dec 01;32(11):7453-7468. doi: 10.1103/physrevb.32.7453. PMID: 9936891.
Copy Download .nbib Format: NLM
Equilibration of crystal surfaces.

Physical review. B, Condensed matter

Duxbury PM, Selke W.
PMID: 9981178
Phys Rev B Condens Matter. 1995 Dec 15;52(24):17468-17479. doi: 10.1103/physrevb.52.17468.

No abstract available.

Cite
Duxbury PM, Selke W. Equilibration of crystal surfaces. Phys Rev B Condens Matter. 1995;52(24):17468-17479doi: 10.1103/physrevb.52.17468.
Duxbury, P. M., & Selke, W. (1995). Equilibration of crystal surfaces. Physical review. B, Condensed matter, 52(24), 17468-17479. https://doi.org/10.1103/physrevb.52.17468
Duxbury, and Selke. "Equilibration of crystal surfaces." Physical review. B, Condensed matter vol. 52,24 (1995): 17468-17479. doi: https://doi.org/10.1103/physrevb.52.17468
Duxbury PM, Selke W. Equilibration of crystal surfaces. Phys Rev B Condens Matter. 1995 Dec 15;52(24):17468-17479. doi: 10.1103/physrevb.52.17468. PMID: 9981178.
Copy Download .nbib Format: NLM
Monte Carlo coarse graining for the three-dimensional axial next-nearest-neighbor Ising model.

Physical review. B, Condensed matter

Kaski K, Selke W.
PMID: 9936176
Phys Rev B Condens Matter. 1985 Mar 01;31(5):3128-3130. doi: 10.1103/physrevb.31.3128.

No abstract available.

Cite
Kaski K, Selke W. Monte Carlo coarse graining for the three-dimensional axial next-nearest-neighbor Ising model. Phys Rev B Condens Matter. 1985;31(5):3128-3130doi: 10.1103/physrevb.31.3128.
Kaski, K., & Selke, W. (1985). Monte Carlo coarse graining for the three-dimensional axial next-nearest-neighbor Ising model. Physical review. B, Condensed matter, 31(5), 3128-3130. https://doi.org/10.1103/physrevb.31.3128
Kaski, and Selke. "Monte Carlo coarse graining for the three-dimensional axial next-nearest-neighbor Ising model." Physical review. B, Condensed matter vol. 31,5 (1985): 3128-3130. doi: https://doi.org/10.1103/physrevb.31.3128
Kaski K, Selke W. Monte Carlo coarse graining for the three-dimensional axial next-nearest-neighbor Ising model. Phys Rev B Condens Matter. 1985 Mar 01;31(5):3128-3130. doi: 10.1103/physrevb.31.3128. PMID: 9936176.
Copy Download .nbib Format: NLM
Policies for biosimilar uptake in Europe: An overview.

PloS one

Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S.
PMID: 29284064
PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017.

BACKGROUND: Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.OBJECTIVES: The aim of this article is to provide an overview of different initiatives and policies that...

Cite
Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017;12(12):e0190147doi: 10.1371/journal.pone.0190147.
Moorkens, E., Vulto, A. G., Huys, I., Dylst, P., Godman, B., Keuerleber, S., Claus, B., Dimitrova, M., Petrova, G., Sović-Brkičić, L., Slabý, J., Šebesta, R., Laius, O., Karr, A., Beck, M., Martikainen, J. E., Selke, G. W., Spillane, S., McCullagh, L., Trifirò, G., Vella Bonanno, P., Mack, A., Fogele, A., Viksna, A., Władysiuk, M., Mota-Filipe, H., Meshkov, D., Kalaba, M., Mencej Bedrač, S., Fürst, J., Zara, C., Skiöld, P., Magnússon, E., & Simoens, S. (2017). Policies for biosimilar uptake in Europe: An overview. PloS one, 12(12), e0190147. https://doi.org/10.1371/journal.pone.0190147
Moorkens, Evelien, et al. "Policies for biosimilar uptake in Europe: An overview." PloS one vol. 12,12 (2017): e0190147. doi: https://doi.org/10.1371/journal.pone.0190147
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017. PMID: 29284064; PMCID: PMC5746224.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Reply: Medicolegal research: A key to the locked door of patient expectations.

The Journal of thoracic and cardiovascular surgery

Palaniappan A, Sellke FW.
PMID: 33516460
J Thorac Cardiovasc Surg. 2021 Jan 27; doi: 10.1016/j.jtcvs.2020.12.088. Epub 2021 Jan 27.

No abstract available.

Cite
Palaniappan A, Sellke FW. Reply: Medicolegal research: A key to the locked door of patient expectations. J Thorac Cardiovasc Surg. 2021;doi: 10.1016/j.jtcvs.2020.12.088.
Palaniappan, A., & Sellke, F. W. (2021). Reply: Medicolegal research: A key to the locked door of patient expectations. The Journal of thoracic and cardiovascular surgery, . https://doi.org/10.1016/j.jtcvs.2020.12.088
Palaniappan, Ashwin, and Sellke, Frank W. "Reply: Medicolegal research: A key to the locked door of patient expectations." The Journal of thoracic and cardiovascular surgery vol. (2021). doi: https://doi.org/10.1016/j.jtcvs.2020.12.088
Palaniappan A, Sellke FW. Reply: Medicolegal research: A key to the locked door of patient expectations. J Thorac Cardiovasc Surg. 2021 Jan 27; doi: 10.1016/j.jtcvs.2020.12.088. Epub 2021 Jan 27. PMID: 33516460.
Copy Download .nbib Format: NLM
Medical malpractice litigations involving aortic dissection.

The Journal of thoracic and cardiovascular surgery

Palaniappan A, Sellke F.
PMID: 33229180
J Thorac Cardiovasc Surg. 2020 Oct 29; doi: 10.1016/j.jtcvs.2020.10.064. Epub 2020 Oct 29.

OBJECTIVES: Medical malpractice litigation arises when a discrepancy exists between a patient's expectation of acceptable medical care and the care the patient receives. Aortic dissection is a frequently misdiagnosed and often-fatal condition. The purpose of this study was to...

Cite
Palaniappan A, Sellke F. Medical malpractice litigations involving aortic dissection. J Thorac Cardiovasc Surg. 2020;doi: 10.1016/j.jtcvs.2020.10.064.
Palaniappan, A., & Sellke, F. (2020). Medical malpractice litigations involving aortic dissection. The Journal of thoracic and cardiovascular surgery, . https://doi.org/10.1016/j.jtcvs.2020.10.064
Palaniappan, Ashwin, and Sellke, Frank. "Medical malpractice litigations involving aortic dissection." The Journal of thoracic and cardiovascular surgery vol. (2020). doi: https://doi.org/10.1016/j.jtcvs.2020.10.064
Palaniappan A, Sellke F. Medical malpractice litigations involving aortic dissection. J Thorac Cardiovasc Surg. 2020 Oct 29; doi: 10.1016/j.jtcvs.2020.10.064. Epub 2020 Oct 29. PMID: 33229180.
Copy Download .nbib Format: NLM
Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01; doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate the...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose. Am Heart J. 2021;doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose. American heart journal, . https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose." American heart journal vol. (2021). doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose. Am Heart J. 2021 Nov 01; doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 107 entries